The U.S. Food and Drug Administration has requested earlier in February 2020 the withdrawal of the weight-loss medicine Belviq® and Belviq XR (lorcaserin) from the American market.
The request is based on the analysis of full data from the CAMELLIA-TIMI 61 trial showing a negative benefit-risk profile of lorcaserin. Indeed, lorcaserin is associated with an increased risk of cancer, including pancreatic, colorectal and lung cancer. During CAMELLIA-TIMI 61 trial, one additional cancer was reported per 470 patients treated with Belviq® for one year.
Also, the U.S. Food and Drufg Administration has alerted the patients to stop taking lorcaserin and talk to their doctors about other alternatives for weight loss.